Ameneh Khatami

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study
    Ameneh Khatami
    Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre and Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 31:1069-73. 2012
  2. ncbi Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
    Vaccine 30:2831-8. 2012
  3. ncbi The epidemiology of meningococcal disease and the impact of vaccines
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, CCVTM, Churchill Hospital, Oxford, OX3 7LJ, UK
    Expert Rev Vaccines 9:285-98. 2010
  4. ncbi Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
    Pediatr Infect Dis J 30:197-202. 2011
  5. ncbi Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood
    A Khatami
    Oxford Vaccine Group, University of Oxford, CCVTM, Churchill Drive, Churchill Hospital, Oxford, OX3 7LJ, UK
    Clin Vaccine Immunol 18:2038-42. 2011

Detail Information

Publications5

  1. ncbi Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study
    Ameneh Khatami
    Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre and Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    Pediatr Infect Dis J 31:1069-73. 2012
    ..We evaluated whether these differences persisted to later childhood, following a preschool booster of DTaP-IPV at 3½ years of age...
  2. ncbi Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
    Vaccine 30:2831-8. 2012
    ..We evaluated the persistence of bactericidal antibodies through early childhood, following infant immunisation with varying schedules of MenACWY-CRM(197) vaccine...
  3. ncbi The epidemiology of meningococcal disease and the impact of vaccines
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, CCVTM, Churchill Hospital, Oxford, OX3 7LJ, UK
    Expert Rev Vaccines 9:285-98. 2010
    ..Development of vaccines for prevention of serogroup B disease in industrialized nations and serogroup A conjugate vaccines for Africa could lead to global control of meningococcal disease...
  4. ncbi Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial
    Ameneh Khatami
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
    Pediatr Infect Dis J 30:197-202. 2011
    ..Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) wane after early infant immunization...
  5. ncbi Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood
    A Khatami
    Oxford Vaccine Group, University of Oxford, CCVTM, Churchill Drive, Churchill Hospital, Oxford, OX3 7LJ, UK
    Clin Vaccine Immunol 18:2038-42. 2011
    ..Sustaining high levels of antibody through booster vaccination in this cohort is likely necessary to avoid a resurgence of disease in the decade ahead...